

Irene Caruso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5215511/publications.pdf>

Version: 2024-02-01

15
papers

260
citations

1162889

8
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

433
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes and cancer: Pathophysiological fundamentals of a "dangerous affair"™. Diabetes Research and Clinical Practice, 2018, 143, 378-388.	1.1	58
2	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. Trends in Endocrinology and Metabolism, 2019, 30, 578-589.	3.1	43
3	Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. Metabolites, 2022, 12, 183.	1.3	31
4	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism: Clinical and Experimental, 2020, 104, 154045.	1.5	23
5	SGLT-2 inhibitors as cardio-renal protective agents. Metabolism: Clinical and Experimental, 2022, 127, 154937.	1.5	20
6	Reduction of hypoglycaemia, lifestyle modifications and psychological distress during lockdown following SARS-CoV-2 outbreak in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2021, 37, e3404.	1.7	19
7	Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2020, 170, 108478.	1.1	14
8	The diabetic lung: An easy target for SARS-CoV-2?. Diabetes/Metabolism Research and Reviews, 2020, 36, e3346.	1.7	11
9	Role of Glucose-Lowering Medications in Erectile Dysfunction. Journal of Clinical Medicine, 2021, 10, 2501.	1.0	9
10	Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection. Metabolism: Clinical and Experimental, 2020, 109, 154272.	1.5	8
11	Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis. Frontiers in Endocrinology, 2022, 13, 846903.	1.5	8
12	Diabetes in the Time of COVID-19: A Twitter-Based Sentiment Analysis. Journal of Diabetes Science and Technology, 2020, 14, 1131-1132.	1.3	6
13	GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time. Diabetes Care, 2022, 45, e30-e31.	4.3	5
14	Diabetic foot: clinical approach. Minerva Orthopedics, 2022, 73, .	0.1	3
15	Sodium-glucose cotransporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?. Diabetes, Obesity and Metabolism, 2021, 23, 2194-2196.	2.2	2